Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

395
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
395
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mitochondrial Dynamic Proteins MiD49 and MiD51 as Novel Targets of Cardioprotection.

Cells·2026
Same author

The Fatty Acid Transporter CD36 Mediates Uptake, Biodistribution, and Cardioprotection by Small Extracellular Vesicles From HEK293 Cells.

Journal of extracellular vesicles·2026
Same author

Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.

European heart journal·2026
Same author

An activator of phosphatidylinositol 3-kinase alpha restores cardioprotection from ischaemia/reperfusion injury in mice with coronary atherosclerosis or insulin resistance.

Cardiovascular research·2025
Same author

The contribution of cardiomyocyte hypercontracture to the burden of acute myocardial infarction: an update.

Basic research in cardiology·2025
Same author

SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity.

Circulation research·2024

相关实验视频

Updated: May 7, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.6K

新型选择性心脏肌肉素向抑制剂缓解心肌缺血症-再输血损伤

Nur Liyana Mohammed Yusof1,2, Derek M Yellon1, Sean M Davidson3

  • 1The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.

Cardiovascular drugs and therapy
|January 4, 2025
PubMed
概括

心脏肌蛋白向抑制剂 (CMIs) 在降低缺血和再注射 (IR) 损伤后心脏损伤方面表现有前途. 这些药物限制心肌细胞过度收缩,在红外环境中提供潜在的心脏保护.

关键词:
一个正式的官员.过度收缩症是一种超收缩症.缺血 缺血是因为缺血.马瓦卡姆特恩是什么意思心肌梗塞的心脏病发作再 perfusion 的意思是重新输注.

更多相关视频

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

27.5K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

5.6K

相关实验视频

Last Updated: May 7, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.6K
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

27.5K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

5.6K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 细胞生物学 细胞生物学

背景情况:

  • 重灌对于限制心肌梗塞至关重要,但可以诱导心肌细胞过度收缩.
  • 心脏肌蛋白向抑制剂 (CMIs),如Mavacamten (MYK-461) 和Aficamten (CK-274),已被批准用于心脏超收缩性,并在临床试验中是安全的.

研究的目的:

  • 调查CMI的心脏保护潜力,以减少缺血-再输血 (IR) 损伤期间的超收缩和心脏病发作大小.
  • 测试CMI可以通过限制心肌细胞过度收缩来减轻IR诱导的心脏损伤的假设.

主要方法:

  • 成年大鼠心肌细胞 (ARVC) 用于在ATP耗尽后在体外评估CMI抑制高收缩.
  • 在体内研究中,麻醉后的老鼠接受了30分钟的冠状动脉绑定,随后进行了2小时的再注血,在再注血之前给予CMI或载体.
  • 使用化四染色量化心脏病发作的大小,并通过组织学染色评估过度收缩. 缺血预制 (IPC) 作为积极对照.

主要成果:

  • 在实验室中,CMIs有效抑制了ARVC超收缩.
  • 与载体治疗相比,MYK-461和CK-274在体内显著减少了心脏病发作的大小.
  • 虽然IPC减少了收缩带缩,但CMIs没有,可能是由于测试限制. 抑制PI3Kα与GDC-0326废除了CK-274介导的保护和减少了AKT酸化.

结论:

  • 在IR损伤的背景下,CMI显示出新的心脏保护作用.
  • 这项研究强调了CMI作为缓解心脏再输伤害的潜在治疗剂.